AKT1 and cervical cancer: In addition, treatment with the AKT inhibitor LY294002 (20 μM) for 6 h significantly blocked the effect of SNCG on cervical cancer growth (Fig. 5b), suggesting that AKT signaling was involved in SNCG-induced cervical cancer growth.